Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Major Depressive Disorder (PSIPET)
NCT04630964Phase 2Completed
- Start
- Jan 2021
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD). Started Jan 2021; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04630964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630964.